Morgan Stanley Acurx Pharmaceuticals, Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 106,201 shares of ACXP stock, worth $73,278. This represents 0.0% of its overall portfolio holdings.
Number of Shares
106,201
Previous 46,201
129.87%
Holding current value
$73,278
Previous $87,000
1.15%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ACXP
# of Institutions
31Shares Held
1.42MCall Options Held
13.6KPut Options Held
4K-
Vanguard Group Inc Valley Forge, PA529KShares$365,2500.0% of portfolio
-
Prospect Financial Services LLC Melville, NY329KShares$227,0620.15% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$101,0840.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA48.4KShares$33,3780.0% of portfolio
-
State Street Corp Boston, MA43.5KShares$29,9910.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $7.97M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...